Kennametal Inc
Change company Symbol lookup
Select an option...
KMT Kennametal Inc
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
BAC Bank of America Corp
WFC Wells Fargo & Co

Industrials : Machinery | Small Cap Blend
Company profile

Kennametal Inc. is a supplier of tooling, engineered components and materials consumed in production processes. The Company operates through two segments: Industrial and Infrastructure. The Industrial segment generally serves customers that operate in industrial end markets, such as transportation, general engineering, aerospace and defense. The Infrastructure segment generally serves customers that operate in the earthworks and energy sectors supporting primary industries, such as oil and gas, power generation, underground, surface and hard-rock mining, highway construction and road maintenance. It provides wear-resistant products, application engineering and services backed by material science serving customers across various sectors. The Company's product offerings include a selection of standard and customized technologies for metalworking, such as metal cutting tools, tooling systems and services, as well as materials, such as cemented tungsten carbide products and super alloys.

Closing Price
Day's Change
0.59 (2.13%)
B/A Size
Day's High
Day's Low

10-day average volume:

NYT: Trump identifies five drugmakers most likely to produce a viable COVID-19 vaccine

3:07 pm ET June 3, 2020 (MarketWatch)

The Trump administration has reportedly named five drugmakers that it expects to be the most likely to produce a viable COVID-19 vaccine, according to The New York Times (, which cited people familiar with the matter. This includes AstraZeneca (AZN.LN) in combination with Oxford University, Johnson & Johnson (JNJ), Moderna Inc. (MRNA), Merck & Co. Inc. (MCK), and Pfizer in combination with BioNTech SE (BNTX). With the exception of Merck, Pfizer, and BioNTech, shares of those companies were up in afternoon trading on Wednesday. Inovio Pharmaceuticals Inc. (INO), an early vaccine contender, was not included in the Times' report. Its stock was down 10.8%. Much of the nation's hopes for an economic recovery are tied to the development of a vaccine that can successfully prevent people from becoming infected with COVID-19. The administration has tirelessly promoted the idea that a vaccine can be developed by the end of the year; however, executives at J&J and Merck have pointed out that the research and development process can take years to develop a safe, efficacious vaccine. Merck CEO Ken Frazier recently told the Financial Times a 12- to 18-month timeline is "very aggressive."

-Jaimy Lee; 415-439-6400;

(END) Dow Jones Newswires

June 03, 2020 15:07 ET (19:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.